About the Author(s)


Phumzile M. Shaku symbol
Anova Health Institute, Tzaneen, South Africa

Kate Rees Email symbol
Anova Health Institute, Johannesburg, South Africa

Department of Community Health, School of Public Health, University of the Witwatersrand, Johannesburg, South Africa

Barry Mutasa symbol
Anova Health Institute, Polokwane, South Africa

Christina Maluleke symbol
Anova Health Institute, Tzaneen, South Africa

Steven Mashele symbol
Department of Health, Mopani District, Giyani, South Africa

Christine Njuguna symbol
Anova Health Institute, Johannesburg, South Africa

Citation


Shaku PM, Rees K, Mutasa B, Maluleke C, Mashele S, Njuguna C. Programmatic outcomes of adolescents in differentiated service delivery models in South Africa. S Afr J Infect Dis. 2025;40(1), a733. https://doi.org/10.4102/sajid.v40i1.733

Note: Additional supporting information may be found in the online version of this article as Online Appendix 1.

Original Research

Programmatic outcomes of adolescents in differentiated service delivery models in South Africa

Phumzile M. Shaku, Kate Rees, Barry Mutasa, Christina Maluleke, Steven Mashele, Christine Njuguna

Received: 11 Mar. 2025; Accepted: 20 May 2025; Published: 16 July 2025

Copyright: © 2025. The Author(s). Licensee: AOSIS.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Adolescents living with HIV face barriers that impede adherence and retention. Differentiated service delivery (DSD) models aim to improve retention and viral suppression (VS), but there is limited programmatic evidence from South Africa on DSD outcomes.

Objectives: This study aimed to measure 12 month retention and VS proportions in adolescents enrolled in DSD and clinic-based care, and measure the association between 12 month retention, VS and covariates.

Method: A retrospective cohort study was conducted in the Mopani District, Limpopo province, using TIER.Net data. The study included adolescents aged 10–19 years enrolled in DSD between 01 September 2019 and 30 September 2022, and those eligible for DSD with viral load < 50 copies/mL. The study measured 12-month retention and VS proportions. Multivariable logistic regression measured association among 12-month retention, VS and exposure variables.

Results: A total of 646 adolescents in DSD and 1282 in clinic-based care were included. Twelve-month retention was 92.7% (599/646) in DSD and 89.0% (1141/1282) in clinic-based care. There was no association between 12-month retention and being enrolled in DSD versus clinic-based care. Twelve-month VS (< 50 copies/mL) was 63.5% (251/395) in DSD, compared to clinic-based care 51.0% (494/969). In multivariable regression, being on DSD was associated with higher VS at < 50 copies/mL (Adjusted Odds Ratio [AOR] 1.6; 95% confidence interval: 1.2–2.1; p < 0.001) than clinic-based care.

Conclusion: Differentiated service delivery improved VS in adolescents in a rural setting and should be prioritised to improve outcomes.

Contribution: Differentiated service delivery improves adolescent VS in a rural setting.

Keywords: adolescents; differentiated service delivery models; HIV; retention; viral suppression; outcomes.

Introduction

South Africa has the largest antiretroviral therapy (ART) programme globally, with approximately 7.6 million people living with HIV and 5.6 million receiving ART.1 In 2022, estimates from the Thembisa Model reported an overall HIV prevalence of 12.6%, including 1.2% among children aged 0–14 years and 6.0% among adolescents and youth aged 15–24 years.2

South Africa aims to meet the Joint United Nations Programme on HIV/AIDS (UNAIDS) 95-95-95 targets by 2030.3 However, the HIV care cascade for children and adolescents under 15 years is lagging, with 81% diagnosed, 71% on ART and 59% being virally suppressed.3

Access to ART for adolescents living with HIV is hindered by barriers such as frequent clinic visits, unstructured lives and long service waiting times.4 Non-disclosure and delayed disclosure of HIV status are major barriers to adherence.5 Anticipated stigma and fear of HIV status discovery may prevent clinic attendance, affecting retention.6 To improve retention, the World Health Organization (WHO) expanded differentiated service delivery (DSD) eligibility from 2017 to include adolescents and children as young as 2 years old.7 Differentiated service delivery is a client-centred approach that tailors and streamlines HIV services to the needs and circumstances of People Living with HIV (PLHIV), reducing clinic visits and offering community-based services to improve outcomes such as viral suppression (VS) and retention.8,9

In this study, DSD refers to differentiated ART delivery for stable adolescents as outlined in the South African adherence guidelines for HIV, TB and non-communicable diseases.10 Stable adolescents on DSD receive a repeat prescription and treatment from the Central Chronic Dispensing and Distribution programme (CCMDD).10 Since 2016, South Africa adopted DSD for stable adults over 18 years on ART and other chronic medications.11 In 2020, with updates in 2023, eligibility was expanded to include children and adolescents who met specific criteria10,12: (1) aged five to 18 years; (2) no regimen change or dosage change in the past 3 months; (3) viral load (VL) in the past 12-months < 50 copies/mL; (4) disclosure to the adolescent initiated by the caregiver; (5) no other conditions requiring continuous clinical care. The adolescent or caregiver in the case of younger adolescents voluntarily opts and provides consent for enrolment after receiving information about the models.10

In Mopani District, the following DSD models are implemented: facility-based pick-up points, where clients collect pre-dispensed medication from a designated area; pharmacy fast-lane, where collection of pre-packed medicine parcels is fast-tracked within the facility; external pick-up points, involving the collection of medication from an external service provider; and adherence clubs, which offer group-format services within the facility, with facilitators monitoring client adherence and wellness.10 In all DSD models, a 2–3-month supply of pre-packed ART is provided and clinical visits are scheduled every 6 months.

Fifty-eight facilities in Mopani District offer youth-friendly services through Youth Care Clubs (YCC), which provide integrated HIV clinical care, pre-packed ART, psychosocial support and comprehensive sexual and reproductive health services to adolescents.13 The YCC model includes adolescents and youths living with HIV who are newly initiated on ART as well as those on ART with suppressed or unsuppressed VLs, to foster peer learning. Once adolescents are stable and meet the eligibility criteria, they are enrolled in one of the three DSD models and receive pre-packed medicine parcels from CCMDD within the YCCs.

Differentiated service delivery has improved retention and VS among adolescents and youth in Sub-Saharan Africa.14 A systematic review found youth-friendly clinics and community-based ART were effective in improving VS and retention in those aged 10–24 years.14 In Lesotho, districts with DSD models, such as teenage clubs, community adherence clubs and peer support groups, had higher retention rates (73%) compared to those without (63%).15 A South African study reported a 94.3% retention rate at 12 months among adolescents and youth aged 12–25 years in DSD models.16

However, evidence on the effectiveness of scaled-up DSD models for adolescents aged 10–19 years in South Africa, particularly in rural areas like Mopani District in Limpopo province, is limited. There is also a scarcity of information on retention and VS across different service delivery modalities. This study aimed to: (1) assess the proportion of adolescents sustaining VS and retention at 12 months in DSD models compared to clinic-based care; (2) evaluate the association between demographic and clinical characteristics for 12-month retention and VS.

Research methods and design

Study design

We conducted a cross-sectional study using routinely collected programmatic data from TIER.Net, an electronic register containing clinical and demographic information of people with HIV and tuberculosis.

Study setting

The study was conducted in Mopani District, in the north-eastern part of the Limpopo province. Limpopo province has an estimated population of 6 572 721.17 The Mopani District with five sub-districts: Ba-Phalaborwa, Greater Giyani, Greater Letaba, Greater Tzaneen and Maruleng, has a population of 1 372 873.17.18 The HIV prevalence in the Limpopo province is 8.9% translating to an estimated 570 000 people.19 There are 104 primary healthcare facilities, 3 non-medical sites and 8 hospitals providing HIV treatment and care for adolescents.18 The study included 113 facilities providing DSD.

Study population
Inclusion criteria

This study included two groups of adolescents aged 10–19 years: (1) enrolled in DSD models between 01 September 2019 and 30 September 2022; or (2) receiving clinic-based care defined as receiving routine HIV care comprising frequent clinic visits, with at least one documented VL < 50 copies/mL between 01 September 2019 and 30 September 2022 and potentially eligible for DSD. Reasons for not enrolling adolescents in clinic-based care included missed opportunities where the clinician did not notice eligibility, failure to meet eligibility criteria, such as being pregnant or lacking a valid identity document, or the client’s preference for clinic-based care.

Exclusion criteria

The study excluded adolescents who: (1) were lost to follow-up, died or transferred out before 01 September 2019; (2) enrolled in DSD or had their first VL < 50 copies/mL from 01 October 2022; (3) were in clinic-based care and did not have at least one VL < 50 copies/mL between 01 September 2019 and 30 September 2022.

Sampling

TIER.Net was used as the sampling frame. Demographic and clinical data were extracted for adolescents aged 10–19 years who met the inclusion criteria from 113 health facilities.

Study variables

For adolescents to achieve and maintain VS, they must be consistently retained in care. The study focused on two outcomes:

  1. Twelve-month retention in care, defined as still in care for 365 days or more after DSD enrolment date or eligibility date. Those transferring out to another clinic, died or lost to follow-up before 365 days were classified as not retained. Lost to follow-up was defined as clients who missed a clinic appointment by ≥ 12 weeks without known cause, death or transfer out. Transfer out referred to clients who moved their ART care to another facility.

  2. Viral suppression for 12 months is defined as a VL between 8 and 20 months after DSD enrolment date (DSD group) or eligibility date for adolescents in clinic-based care. This wide VL window was selected because of insufficient VLs taken at 12 months for the analysis. In this study, a < 50 copies/mL cut-off was considered VS.20 An additional VL cut-off of < 1000 copies/mL was also reported for VS as per the 95-95-95 UNAIDS VS targets.21 Viral suppression proportions were calculated as total virally suppressed divided by total number of clients with VLs.

    Exposure variables: Demographic variables included gender, age at last visit and sub-district. Clinical variables included dates of VL collection and VL values. Treatment variables included ART start dates, ART regimen at last visit, DSD enrolment date, DSD model, treatment month, treatment outcome and treatment outcome date.

Data analysis

Prior to data analysis, all identifying information were removed. Descriptive statistics were used to describe client characteristics, with continuous variables analysed using mean and standard deviation for normally distributed data, medians and interquartile ranges for skewed data. Categorical variables were described using proportions.

Simple proportions measured the 12-month retention and VS for two cut-offs (< 50 copies/mL and < 1000 copies/mL) in DSD models and clinic-based care. Differences were assessed using Chi-squared Statistics or Fisher’s exact tests.

Multivariable logistic regression was conducted to measure association between outcomes (12-month retention and 12-month VS), and the following exposure variables: study group, age at last visit, gender, ART duration, ART regimen type (first or second-line ART), ART regimen backbone and sub-district.

Antiretroviral therapy duration was defined from ART start date to DSD enrolment date or eligibility date (clinic-based care group). Exposure variables were pre-selected based on known associations with the outcome variables and availability on TIER.Net database. Multivariable Logistic Regression Analysis reported adjusted odds ratios (AOR), 95% confidence intervals (CIs) and p-values (< 0.05 considered significant). Data were analysed using STATA software Version 18.22

Ethical considerations

Ethical approval was obtained from the Human Sciences Research Council’s Research Ethics Committee (REC 3/22/08/18). This study used de-identified TIER.Net data which are routinely collected at healthcare facilities for monitoring purposes, therefore individual consent was not required.

Results

A total of 1935 adolescents met the inclusion criteria. Of these, 1285 (66.5%) and 650 (33.5%) were in the clinic-based care and DSD groups, respectively. Seven adolescents were excluded for death, loss to follow-up or transferred out on or before the DSD enrolment or eligibility date. The final sample included 1928 individuals (n = 646 DSD group and n = 1282 clinic-based care group).

Characteristics of adolescents in differentiated service delivery and clinic-based care groups

Of the 1928 adolescents, 646 (33.5%) were in DSD models and 1282 (66.5%) in the clinic-based care group (Table 1). For the DSD models (n = 646), 26 (4.0%) were in adherence clubs, 239 (37.0%) in external pick-up points and 381 (59.0%) in facility pick-up points. Almost 75%, (n = 475) in DSD were older, aged between 15–19 years (p < 0.001) and 365 (56.5%) were female (p = 0.879). Most adolescents in DSD had been on ART for more than 5 years; ranging from 69.2% to 77.8% across the models, compared to clinic-based care clients (58.1%) (Table 1).

TABLE 1: Characteristics of adolescents enrolled in differentiated service delivery compared to those in clinic-based care.

Most adolescents were on first-line ART, 96.0% for DSD and 95.4% for clinic-based care (p = 0.553). More adolescents in DSD were on dolutegravir-based regimen at the last clinic visit 517 (80.0%), compared to 803 (62.8%) in clinic-based care. Just over a third of adolescents in DSD (35.9%) and clinic-based care (39.2%) were enrolled in Greater Tzaneen sub-district. The exception was for the adherence clubs, where 69.2% (18/26) were enrolled in Ba-Phalaborwa sub-district (Table 1).

Twelve-month retention for adolescents in differentiated service delivery group and clinic-based care

At the end of the study period, 81.7% (1576/1928) adolescents remained in care, 5.5% (106/1928) were lost to follow-up, 0.9% (18/1928) had died and 11.8% (228/1928) had transferred out (Data not shown).

Overall, 12-month retention on ART was comparable; 92.7% (95% CI: 90.4–94.6; 599/646) for the DSD group versus 89.0% (95% CI: 87.2–90.7; 1141/1282) for clinic-based group (proportion difference = 3.7%, p = 0.009) as shown in Figure 1 and mentioned in Table 2.

FIGURE 1: Twelve-month retention on antiretroviral therapy comparing differentiated service delivery to clinic-based care, and differentiated service delivery modalities.

TABLE 2: Twelve-month retention for adolescents enrolled in differentiated service delivery compared to those in clinic-based care.

Within the DSD modalities (n = 646), facility pick-up points had the highest 12-month ART retention at 96.1% (366/381), compared to 92.3% (24/26) for adherence clubs and 87.5% (209/239) for external pick-up-points as shown in Figure 1.

Factors associated with 12 months antiretroviral therapy retention in the total study population

In Multivariable Logistic Regression Analysis, there was no difference between DSD (AOR = 1.1; 95% CI: 0.7–1.7; p = 0.621) versus clinic-based care (Table 3). Factors associated with increased odds of 12-month retention were: being on ART for 1–5 years (AOR = 4.0; 95% CI: 2.4–6.7; p < 0.001), and > 5 years (AOR = 5.2; 95% CI: 3.2–8.5; p < 0.001) compared to below 1 year, being on a dolutegravir-based ART regimen, (AOR = 7.4; 95% CI: 5.0–10.9; p = 0.010), and a lopinavir/ritonavir-based ART regimen (AOR = 2.5; 95% CI: 1.3–4.8; p = 0.005) compared to an efavirenz/nevirapine-based ART regimen, and being enrolled within Giyani sub-district compared to Ba-Phalaborwa (AOR = 2.3; 95% CI: 1.2–4.4; p = 0.010) (Table 3).

TABLE 3: Logistic regression for factors associated with 12-month retention on differentiated service delivery versus clinic-based care.

Older age (15–19 years) was associated with decreased odds of 12-month ART retention (AOR = 0.6; 95% CI: 0.4–0.8; p = 0.002) compared to adolescents aged 10–14 years (Table 3).

Factors associated with 12-month retention for differentiated service delivery group only (n = 646)

In multivariable logistic regression, there was no association between DSD Models and 12-month retention as shown in Online Appendix 1 Table 1-A1.

Viral suppression for adolescents in differentiated service delivery and clinic-based care groups

Overall, 70.7% (1364/1928) of adolescents had a VL done during the follow-up period. Of these, 54.6% (745/1364) had VS < 50 copies/mL at 12 months (data not shown).

Among adolescents in the DSD group 61.2% (395/646) had a 12-month VL done compared to 75.6% (969/1282) in the clinic-based group (Table 4).

TABLE 4: Twelve-month viral load suppression (< 50 copies/mL and < 1000 copies/mL) for differentiated service delivery modalities compared to clinic-based care group.

Twelve-month VS (< 50 copies/mL) was 63.5% (95% CI: 58.6–68.3; 251/395) for DSD group, compared to 51.0% (95% CI: 47.8–54.2; 494/969) in the clinic-based care group (proportion difference: 12.5%, p < 0.001) (Table 4).

Twelve-month VS (< 1000 copies/mL) was 93.4% (95% CI: 90.5–95.7; 369/395) for those in DSD group, compared to 85.1% (95% CI: 82.7–87.3; 825/969) in clinic-based care (proportion difference = 8.3%; p < 0.001) (Table 4).

Twelve-month VLs were done in 80.8% (21/26) of adolescents in adherence clubs, 58.6% (140/239) in external pick-up points and 61.4% (234/381) in facility pick-up points (Table 4).

Twelve-month suppression (< 50 copies/mL) was lowest for adherence clubs 52.4%, compared to 65.0% for facility pick-up points and 62.9% for external pick-up points. At 12 months, VS at < 1000 copies/mL was similar for adherence clubs and facility pick-up points (95.0%) compared to 90.7% for external pick-up points (Table 4).

Low-level viremia (50–999 copies/mL) was observed in 32.9% (449/1364) of the cohort. Adolescents in clinic-based care showed a higher proportion of low-level viremia, with 34.2% (331/969) compared to 29.9% (118/395) in DSD (Data not shown).

Factors associated with 12-month viral suppression

Being enrolled in DSD versus clinic-based care increased the odds of 12-month VS (< 50 copies/ml) after adjusting for age at last clinic visit, gender, ART duration, ART regimen type, ART regimen backbone and sub-district, (AOR = 1.6 95% CI 1.2–2.1; p < 0.001). No other variables were significantly associated with VS < 50 copies/mL (Table 5).

TABLE 5: Multivariable logistic regression for factors associated with 12-month viral load suppression at < 50 copies/mL (n = 1360) and < 1000 copies/mL cut-off (n = 1360).

Similarly, at <1000 copies/mL, being enrolled on DSD model had increased odds of 12-month VS (AOR = 2.2; 95% CI: 1.4–3.5; p = 0.001) after adjusting for current age, gender, ART duration, ART regimen type, ART regimen backbone and sub-district. Being on ART over 5 years was also associated with increased odds of VS at < 1000 copies/mL (AOR = 2.3; 95% CI: 1.2–4.2; p = 0.009) (Table 5).

Factors associated with 12-month viral suppression for differentiated service delivery group only (N = 646)

In multivariable logistic regression, there was no association between DSD model and 12-month VS (< 50 copies/mL and < 1000 copies) after adjusting for age at the last visit, gender, ART duration, ART regimen type, ART regimen backbone and sub-district (Online Appendix 1 Table 2-A1).

Discussion

This study found that VS (< 50 copies/mL and < 1000 copies/mL) in adolescents in DSD was significantly higher than clinic-based care even in multivariable logistic analysis. However, ART retention was similar within DSD (92.7%) and clinic-based care (89.0%) for adolescents.

We found comparable retention in the DSD (92.7%) and clinic-based group (89.0%). In Mopani District, stable adolescents who are not eligible for DSD because of no valid identity document, for instance may receive multi-month dispensing at the clinic thereby enjoying similar benefits to those in facility-based DSD Models. This may contribute to the comparable retention in DSD and clinic-based care.

In our study, most adolescents (59%) accessed medications through facility pick-up points, while only 4% were in adherence clubs. Facility-based pick-up points are more common than external ones in rural areas because of the logistical challenges and limited infrastructure in the latter. In Mopani District, the scarcity of external pick-up points makes facility-based DSD the most accessible option. Starting in March 2020, during COVID-19 restrictions, there was a rapid shift from facility-based DSD to external pick-up points to reduce facility congestion and promote social distancing.23 However, post-COVID-19, many adherence clubs in the Mopani District were not reinstated. Data on adolescent preferences for DSD modalities are limited. A Ugandan study contrasts our data by reporting that adolescents preferred community-based client-led groups for their peer support.24

Within DSD models, facility pick-up points had the highest proportion of ART retention at 12 months (96.1%), although no association was found between DSD modality and 12-month retention in multivariable analysis. A South African study also showed higher loss to follow-up in community-based than clinic-based clubs among 18–24-year-olds.25

Adolescents with longer ART duration (1–5 years or > 5 years) had improved retention than those on ART for < 1 year. However, this finding may be biased, as in adolescents in long-term care on ART for > 1 year are likely to have remained adherent and remain engaged in care. In contrast, some studies report that longer treatment duration results in treatment fatigue and poor ART adherence among adolescents.26,27,28 Adolescents on dolutegravir-based regimens showed better retention than those on efavirenz or nevirapine-based regimens. This supports existing evidence that fewer side effects contribute to improved adherence. Clinic-based support groups may also improve ART knowledge and motivation. In this study, older adolescents (15–19 years) had lower 12-month retention than younger ones (10–14 years), possibly because of caregiver support for younger adolescents. This underscores the need for adolescent-friendly DSD models. Lower retention among adolescents aged 15–19 years was reported in South Africa and Namibia.29,30 In DSD models (n = 646), no significant association was found between DSD modality and 12-month retention after adjusting for covariates.

Overall VL coverage in this study was low, with only 70.7% having a VL. Other resource-limited settings have shown similar coverage, ranging from 54% to 68% in KwaZulu-Natal, South Africa, to 80.3% in Uganda.31,32 Barriers to adequate VL coverage include missing clinic appointments because of conflicting school commitments and caregivers collecting on behalf of the adolescents.27 While many Mopani District health facilities provide ART services, most do not offer laboratory services on weekends. To track the efficacy of ART, yearly VL testing is imperative. Synchronising prescription renewal with VL collection date and integrating VL collection at community and school health services may also improve VL coverage.

Viral suppression proportion at < 50 copies/mL cut-off was higher in DSD adolescents (63.5%), compared to clinic-based care (51.0%). Enrolment in DSD models was significantly associated with VS at < 50 copies/mL and < 1000 copies/mL after adjusting for confounders. At a higher VL threshold (< 400 copies/mL), data from six African countries reported VS ranging from 79% to 85% among clinically stable children and adolescents aged 0–19 years receiving multi-month dispensing.33 A similar pattern was observed for the < 1000 copies/mL threshold. A study from Malawi demonstrated that adolescents aged 10–19 years in teen clubs had better VS (cut-off < 1000 copies/mL) than standard clinical care.34 Another study in children and adolescents aged 2–18 years reported improved VS (< 1000 copies/mL) from 64% to 92% before and after implementing multi-month dispensing.35

Interestingly, despite a high proportion of suppression at < 1000 copies/mL, low-level viremia was common in 32.9% (449/1634) of the cohort as in other Southern African settings.36 The reasons for this are not clear, but most likely relate to suboptimal adherence.37

Within DSD Models, the proportion of VS (< 50 copies/mL) was highest within facility pick-up points (65.0%) and lowest within adherence clubs (52.4%). Adolescents at facility pick-up points also receive YCC services, including disclosure and adherence counselling, psychosocial support, sexual and reproductive healthcare, health talks, screening for sexually transmitted infections, tuberculosis and nutrition – these services were not offered in other modalities. This may contribute to enhanced adherence to ART, and consequently improved VS. As adherence clubs include members of different age groups, adherence support might not be adolescent-friendly.

This study had some strengths. This is the first study in South Africa to measure adolescent VS and retention in specific DSD models, such as facility pick-up points and external pick-up points. Moreover, this study contributes to the knowledge on the effectiveness of the DSD model in rural settings, specifically in Mopani District.

The study had several limitations. Because this is an observational study of routine programme data, the DSD and clinic-based groups are likely to be different at baseline. We found a higher proportion of older adolescents and those on ART for longer in DSD models. These adolescents are more likely to be eligible for DSD, have had additional opportunities for enrolment, and healthcare workers feel more comfortable enrolling them. We accounted for these factors in multivariate analysis, but it remains a challenge to evaluate outcomes of DSD in routine programmes. The sample size was small, as DSD models enrolled less than 30% of eligible adolescents in the district during the study period. Adherence clubs had too few participants to compare with other DSD models, preventing proportion difference testing. Only 12-month retention was reported; data beyond this period were unavailable, limiting long-term outcome analysis. Viral load collection was low, restricting the interpretation of VS results to adolescents with available VL results, potentially leading to an under- or over-estimation of VS proportions. Accurate retention data on DSD were unavailable on TIER.Net. The inclusion criteria for adolescents in clinic-based care did not consider high VL after initial suppression (< 50 copies/mL), only capturing a single point in time.

Conclusion

This study highlights the role of DSD in improving VS and retention in care among adolescents. However, low VL coverage is a concern and may be improved by making ART services more accessible to adolescents and synchronising prescription renewal with VL sample collection. Furthermore, the persistence of low-level viremia warrants innovative adherence support without adding to the visit burden.

Acknowledgements

The authors would like to acknowledge everyone who contributed to the study and the Department of Health in Mopani District for permission to use programme data for the study. The authors would also like to acknowledge the District Central Chronic Dispensing and Distribution (CCMDD) Coordinator for the continuous efforts to improve the differentiated service delivery (DSD) programme to respond to adolescent needs. They would also like to specially thank the clinical team and adolescent and youth-friendly team in Mopani District for their dedication to implementing DSD for adolescents to reduce adherence barriers and improve HIV outcomes.

Competing interests

The authors reported that they have received funding from the US President’s Emergency Plan for AIDS Relief (PEPFAR) through the United States Agency for International Development (USAID) under Cooperative Agreement number 674-A-12-00015 to the Anova Health Institute, which may be affected by the research reported in the enclosed publication. The authors have fully disclosed those interests and have implemented an approved plan for managing any potential conflicts arising from their involvement. The terms of these funding arrangements have been reviewed and approved by the affiliated University in accordance with its policy on objectivity in research.

Authors’ contributions

P.M.S. and C.N. were responsible for the conceptualisation, design of the study and writing of the manuscript. B.M., C.N. and P.M.S. contributed to data curation. C.N. contributed to the supervision of the study and data analysis. All authors, P.M.S., K.R., B.M., C.M., S.M. and C.N. have reviewed and approved the final manuscript.

Funding information

This study is made possible by the support of the US President’s Emergency Plan for AIDS Relief (PEPFAR) through the United States Agency for International Development (USAID) under Cooperative Agreement number 674-A-12-00015 to the Anova Health Institute.

Data availability

The data that support the findings of this article are available from the corresponding author, K.R., upon reasonable request.

Disclaimer

The views and opinions expressed in this article are those of the authors and are the product of professional research. They do not necessarily reflect the official policy or position of any affiliated institution, funder, agency or that of the publisher. The authors are responsible for this article’s results, findings and content.

References

  1. The Joint United Nations Programme on HIV/AIDS (UNAIDS). HIV and AIDS estimates [homepage on the Internet]. 2022 [cited 2023 Nov 15]. Available from: https://www.unaids.org/en/regionscountries/countries/southafrica
  2. Human Sciences Research Council. HIV prevalence, by age and sex [homepage on the Internet]. 2023 [cited 2023 Nov 15]. Available from: https://sanac.org.za/wp-content/uploads/2023/05/SANAC-NSP-2023-2028-Web-Version.pdf
  3. South African National AIDS Council (SANAC). National HIV literacy implementation framework [homepage on the Internet]. Pretoria; 2023 [cited 2023 Nov 15]. Available from: https://sanac.org.za/wp-content/uploads/2023/08/National-HIV-Treatment-Literacy-Implementation-Framework.pdf
  4. Van Wyk B, Kriel E, Mukumbang F. Retention in care for adolescents who were newly initiated on antiretroviral therapy in the Cape Metropole in South Africa. S Afr J HIV Med. 2020;21(1):1077. https://doi.org/10.4102/sajhivmed.v21i1.1077
  5. Khangale HMM, Raliphaswa NS, Tshililo AR. HIV status disclosure to adolescents who are perinatally infected in Rustenburg Sub District Northwest Province. Children. 2022;9(12):1989. https://doi.org/10.3390/children9121989
  6. Lamb MR, Fayorsey R, Nuwagaba-Biribonwoha H, et al. High attrition before and after ART initiation among youth (15–24 years of age) enrolled in HIV care. AIDS. 2014;28(4):559–568. https://doi.org/10.1097/QAD.0000000000000054
  7. World Health Organization. Key considerations for differentiated antiretroviral therapy delivery for specific populations: Children, adolescents, pregnant and breastfeeding women and key populations [homepage on the Internet]. 2017 [cited 2023 Nov 15]. Available from: https://creativecommons.org/licenses/by-nc-sa/3.0/igo
  8. International AIDS Society (IAS). What is DSD? [homepage on the Internet]. 2023 [cited 2023 Nov 15]. Available from: https://www.differentiatedservicedelivery.org/about_dsd
  9. Lewis L, Sookrajh Y, Gate K, et al. Differentiated service delivery for people using second-line antiretroviral therapy: Clinical outcomes from a retrospective cohort study in KwaZulu-Natal, South Africa. J Int AIDS Soc. 2021;24(S6):e25802. https://doi.org/10.1002/jia2.25802
  10. National Department of Health. Minimum differentiated models of care package to support linkage to care, adherence and retention in care differentiated models of care standard operating procedures adherence guidelines for HIV, TB and NCDs [homepage on the Internet]. 2023 [cited 2023 Nov 15]. Available from: https://knowledgehub.health.gov.za/system/files/elibdownloads/2023-05/WEB%20VERSION_South%20African%20National%20Differentiated%20Models%20of%20Care%20SOPs%202023_FINAL18042023.pdf
  11. National Department of Health (NDoH). Adherence guidelines for HIV, TB and NCDs | 1 policy and service delivery guidelines for linkage to care, adherence to treatment and retention in care adherence guidelines for HIV, TB and NCDs foreword [homepage on the Internet]. 2016 [cited 2023 Nov 15]. Available from: https://knowledgehub.health.gov.za/system/files/elibdownloads/2023-05/WEB%20VERSION_South%20African%20National%20Differentiated%20Models%20of%20Care%20SOPs%202023_FINAL18042023.pdf
  12. National Department of Health. Minimum package of interventions to support linkage to care, adherence and retention in care standard operating procedures facility-based community-based [homepage on the Internet]. 2020 [cited 2023 Nov 15]. Available from: https://sahivsoc.org/Files/Adherence%20Guidelines%20SOPs%20March20%20revision%20FINAL%20NDOH%20web.pdf
  13. WITS RHI. Youth care clubs (YCCs): An adolescent & youth-friendly HIV treatment & care model. In: Pediatric-adolescent treatment Africa conference [homepage on the Internet]. 2017 [cited 2025 Apr 19]. Available from: https://www.differentiatedservicedelivery.org/wp-content/uploads/RuthHenwood_WitsRH_YouthCareClubs.pdf
  14. Casale M, Carlqvist A, Cluver L. Recent interventions to improve retention in HIV care and adherence to antiretroviral treatment among adolescents and youth: A systematic review. AIDS Patient Care STDs. 2019;33(6):237–252. https://doi.org/10.1089/apc.2018.0320
  15. Amzel A, Srivastava M, Isavwa A, et al. Community-based interventions to reach 95-95-95 for children and adolescents: An exploratory programmatic review from Lesotho. J Acquir Immune Defic Syndr. 2018;78(Suppl. 2):S81–S87. https://doi.org/10.1097/QAI.0000000000001735
  16. Wilkinson L, Moyo F, Henwood P, et al. ART adherence clubs: Outcomes from an innovative model for HIV positive youth in Khayelitsha, South Africa. In: 21st International AIDS Conference [homepage on the Internet]. Durban; 2016 [cited 2024 Jun 10]. Available from: https://mv.ecuo.org/wp-content/uploads/sites/4/2018/03/ABSTRACT-BOOK.-AIDS-2016.-21st-International-AIDS-Conference.-18-22-July-2016.-Durban-South-Africa.pdf
  17. Statistics South Africa. Census: Key statistics [homepage on the Internet]. 2022 [cited 2024 Feb 01]. Available from: https://census.statssa.gov.za/#/province/9/2
  18. Department of Cooperative Governance and Traditional Affairs (COGTA). Mopani district profile and analysis: District development model [homepage on the Internet]. 2020 [cited 2023 Nov 16]. Available from: https://www.cogta.gov.za/ddm/wp-content/uploads/2020/11/Mopani-October-2020.pdf
  19. Human Sciences Research Council. Provincial key findings of the Sixth South African National HIV, Prevalence, Incidence and Behaviour Survey (SABSSM VI): Using research to create a healthier nation [homepage on the Internet]. Polokwane; 2024 [cited 2025 Mar 09]. Available from: https://hsrc.ac.za/special-projects/sabssm-survey-series/sabssm-vi-provincial-dialogue-limpopo-media-pack/
  20. National Department of Health. 2023 ART clinical guidelines for the management of HIV in adults, pregnancy and breastfeeding, adolescents, children, infants and neonates [homepage on the Internet]. Pretoria; 2023 [cited 2024 Aug 07]. Available from: https://knowledgehub.health.gov.za/system/files/elibdownloads/2023-06/National%20ART%20Clinical%20Guideline%202023_06_06%20version%203%20Web.pdf
  21. South African National AIDS Council (SANAC). 2023–2028 National strategic plan for HIV | TB | STIs launch copy [homepage on the Internet]. 2023 [cited 2024 Jul 03]. Available from: https://knowledgehub.health.gov.za/system/files/elibdownloads/2023-04/NSP-HIV-TB-STIs-2023-2028-MARCH20_23-PRINT2.pdf
  22. StataCorp. 2023. Stata Statistical Software: Release 18. College Station, TX: StataCorp LLC.
  23. National Department of Health. CCMDD operations during COVID-19 [homepage on the Internet]. 2020 [cited 2025 Apr 30]. Available from: https://profmoosa.com/wp-content/uploads/2020/10/CCMDD_SOP24_-CCMDD-operations-during-COVID-19-_March2020-Final.pdf
  24. Miyingo C, Mpayenda T, Nyole R, et al. HIV treatment and care of adolescents: Perspectives of adolescents on community-based models in Northern Uganda. HIV/AIDS – Research and palliative care. 2023;15:105–114. https://doi.org/10.2147/HIV.S405393
  25. Hanrahan CF, Schwartz SR, Mudavanhu M, et al. The impact of community-versus clinic-based adherence clubs on loss from care and viral suppression for antiretroviral therapy patients: Findings from a pragmatic randomized controlled trial in South Africa. PLoS Med. 2019;16(5):e1002808. https://doi.org/10.1371/journal.pmed.1002808
  26. Bondarchuk CP, Mlandu N, Adams T, De Vries E. Predictors of low antiretroviral adherence at an urban South African clinic: A mixed-methods study. S Afr J HIV Med. 2022;23(1):1343. https://doi.org/10.4102/sajhivmed.v23i1.1343
  27. Van Wyk B, Davids LA. HIVMED-20-1002.pdf Capetown adherence. S Afr J HIV Med. 2019;20(1):2078–6751. https://doi.org/10.4102/sajhivmed.v20i1.1002
  28. Mugglin C, Haas AD, Van Oosterhout JJ, et al. Long-term retention on antiretroviral therapy among infants, children, adolescents and adults in Malawi: A cohort study. PLoS One. 2019;14(11):e0224837. https://doi.org/10.1371/journal.pone.0224837
  29. Van Wyk BE, Davids LAC. Challenges to HIV treatment adherence amongst adolescents in a low socio-economic setting in Cape Town. S Afr J HIV Med. 2019;20(1):1002. https://doi.org/10.4102/sajhivmed.v20i1.1002
  30. Munyayi FK, Van Wyk BE. Determinants and rates of retention in HIV care among adolescents receiving antiretroviral therapy in Windhoek, Namibia: A baseline cohort analysis. BMC Public Health. 2023;23(1):458. https://doi.org/10.1186/s12889-023-15356-w
  31. Sunpath H, Hatlen TJ, Naidu KK, et al. Targeting the third ‘90’: Introducing the viral load champion. Public Health Action. 2019;8(4):225–231. https://doi.org/10.5588/pha.18.0063
  32. Lubega P, Nalugya SJ, Kimuli AN, et al. Adherence to viral load testing guidelines, barriers, and associated factors among persons living with HIV on ART in Southwestern Uganda: A mixed-methods study. BMC Public Health. 2022;22(1):1268. https://doi.org/10.1186/s12889-022-13674-z
  33. Kim MH, Wanless RS, Caviness AC, et al. Multimonth prescription of antiretroviral therapy among children and adolescents: Experiences from the baylor international pediatric AIDS initiative in 6 African countries. J Acquir Immune Defic Syndr. 2018;78(Suppl. 2):S71–S80. https://doi.org/10.1097/QAI.0000000000001730
  34. Alibi M, Mwapasa V, Ngwalangwa F. Retrospective cohort study comparing antiretroviral treatment outcomes among adolescents in teen clubs and standard care clinics: Blantyre, Malawi. J Int Assoc Provid AIDS Care. 2023;22:23259582231172340. https://doi.org/10.1177/23259582231172340
  35. Casalini C, Bateganya M, Akolo C, et al. Increasing multimonth dispensing of antiretrovirals and assessing the effect on viral load suppression among children and adolescents receiving HIV services in Nigeria. PLoS One. 2023;18(6):e0286303. https://doi.org/10.1371/journal.pone.0286303
  36. Sovershaeva E, Shamu T, Wilsgaard T, et al. Patterns of detectable viraemia among children and adults with HIV infection taking antiretroviral therapy in Zimbabwe. Int J Infect Dis. 2019;78:65–71. https://doi.org/10.1016/j.ijid.2018.10.019
  37. Devendra A, Kohler M, Letsika M, et al. HIV viral suppression in children and adolescents 2 years after transition to dolutegravir: A multicentre cohort study. AIDS. 2024;38(7):1013–1023. https://doi.org/10.1097/qad.0000000000003835


Crossref Citations

No related citations found.